Can Zyprexa (olanzapine) be given through a gastrostomy tube?

Can Zyprexa Be Given Through a G-Tube?

Zyprexa (olanzapine) tablets can be crushed and administered through a gastrostomy tube, but this is an off-label use that requires careful consideration of tube type, flushing protocols, and pharmacist consultation.

Key Administration Considerations

Formulation-Specific Guidance

The FDA label for Zyprexa does not provide specific instructions for enteral tube administration 1. However, ZYPREXA ZYDIS (orally disintegrating tablets) may be the most practical formulation since they dissolve rapidly in saliva and can be administered with or without liquid 1. Standard tablets would require crushing, which carries additional risks.

Critical Safety Requirements

When administering olanzapine through a G-tube, you must:

• Consult a pharmacist before initiating therapy - this is strongly recommended by ESPEN guidelines for all medications given via enteral tubes 2
• Confirm the tube is gastric, not jejunal - drug absorption occurs primarily in the stomach and proximal small bowel, so post-pyloric administration may reduce bioavailability 2, 3
• Use proper ENFit connectors to prevent fatal misconnection errors 2

Step-by-Step Administration Protocol

1. Verify tube position and patency before medication administration 2

2. Prepare the medication:

   • If using standard tablets: crush thoroughly and suspend in water immediately before use
   • If using ZYDIS: dissolve in small amount of water
   • Never mix with other medications - drug-drug interactions and tube occlusion risk 2

3. Flush the tube with 30 mL of water before medication 2, 4

4. Administer the medication immediately after preparation

5. Flush with 30 mL of water after each medication 2, 4

6. Hold enteral feeding - consider timing relative to feeds, as some medications bind to enteral formulas 2

Important Caveats and Pitfalls

Tube Material Matters

Polyurethane tubes are preferable to silicone for medication administration due to better patency retention 2. The tube material can affect drug binding and absorption 2.

Metabolic Monitoring is Critical

Olanzapine carries substantial metabolic risks including weight gain, dyslipidemia, and hyperglycemia 5. These risks may be amplified in patients requiring G-tube feeding who often have complex medical conditions.

Off-Label Responsibility

Using crushed olanzapine tablets through a G-tube is off-label use. You assume additional responsibility for adverse events when prescribing outside the Summary of Product Characteristics 3. Document your clinical rationale clearly.

Avoid Common Errors

• Do not shake ENFit syringes to remove drug residue - this exposes staff to medication and alters dosing 2
• Do not use low-dose tip syringes without understanding the "moat effect" that can alter delivered dose 2
• Do not administer if tube has migrated to post-pyloric position 2

Alternative Considerations

If G-tube administration proves problematic:

• Intramuscular olanzapine is FDA-approved for acute agitation (2.5-10 mg doses) 1
• Intravenous olanzapine has emerging evidence in adults but is off-label and not FDA-approved 6, 7
• Consider alternative antipsychotics with better-established enteral tube data

Quality of Life Impact

The decision to use olanzapine via G-tube should prioritize whether the patient can achieve meaningful symptom control without excessive metabolic burden. In patients with treatment-resistant psychosis who cannot take oral medications, G-tube olanzapine may be justified 8, 5, but requires intensive metabolic monitoring and consideration of whether the benefits outweigh the substantial weight gain and metabolic risks that are particularly pronounced with this agent.